Maze Therapeutics, Inc. (MAZE) has announced a significant underwritten registered offering aimed at raising approximately $150 million in gross proceeds. The offering includes 5.54 million shares of common stock priced at $23.50 each, alongside pre-funded warrants for an additional 850,000 shares at $23.499 per warrant. The closing date for this offering is anticipated around April 23.
This capital raise is crucial for Maze as it will primarily fund the advancement of its research and development initiatives, particularly for its product candidates targeting APOL1-mediated kidney disease and phenylketonuria. The company projects that the net proceeds, alongside its existing cash reserves, will sustain operations through 2029. Following the announcement, Maze’s stock experienced a 4.28% decline in regular trading, closing at $25.69, but saw a slight rebound in after-hours trading.
For market professionals, this offering highlights Maze’s commitment to its R&D pipeline while also indicating potential volatility in its stock as investors react to dilution concerns and funding strategies.
Source: nasdaq.com